GTR Home > Tests > Search results - C1865322[DISCUI]

Apply filters

Showing tests for all 1538 conditions

Compare labs

Your search term can be found in tests with a total of 1538 conditions. Only 1000 conditions are displayed in this filter box. Please type the name of the condition in the search box in this filter to find the specific condition. You can use the filters below to narrow down your results.
If the name of the condition you typed is not present, please try another query or search using the All GTR tab.

  • Hide states

GTR test search results for C1865322[DISCUI]

C Clinical test, R Research test

Showing 1 to 20 of 40 tests for 1538 conditions in 18 labs

CAllNeuro panel

Lab: Centogene AG - the Rare Disease Company University of Rostock Rostock, Mecklenburg-Vorpommern, Germany
Test targets
Methods
  • C Sequence analysis of the entire coding region
Total conditions (602)
Total targets (1038)

CFamilial hemiplegic migraine type 2

Lab: Centogene AG - the Rare Disease Company University of Rostock Rostock, Mecklenburg-Vorpommern, Germany
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

CFamilial Hemiplegic Migraine NextGen Sequencing (NGS) Panel

Lab: PreventionGenetics Marshfield, Wisconsin, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

CFamilial Hemiplegic Migraine 2 (FHM2) via the ATP1A2 Gene

Lab: PreventionGenetics Marshfield, Wisconsin, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

CCACNA1A. NextGeneDx.Complete sequencing by NGS

Lab: Instituto de Medicina Genomica Paterna, Comunidad Valenciana, Spain
Test targets
Methods
  • C Sequence analysis of the entire coding region

CCACNA1A. Complete sequencing

Lab: Instituto de Medicina Genomica Paterna, Comunidad Valenciana, Spain
Test targets
Methods
  • C Sequence analysis of the entire coding region

CSCN1A. Complete sequencing

Lab: Instituto de Medicina Genomica Paterna, Comunidad Valenciana, Spain
Test targets
Methods
  • C Sequence analysis of the entire coding region

CATP1A2. Complete sequencing

Lab: Instituto de Medicina Genomica Paterna, Comunidad Valenciana, Spain
Test targets
Methods
  • C Sequence analysis of the entire coding region

CATP1A2

Lab: Fulgent Clinical Diagnostics Lab Fulgent Diagnostics Temple City, California, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
Total conditions (38)

CFamilial hemiplegic migraine type 2

Lab: Bioarray Elche, Comunidad Valenciana, Spain
Test targets
Methods
  • C Sequence analysis of the entire coding region

CSingle gene testing ATP1A2

Lab: CeGaT GmbH Tuebingen, Baden-Wurttemberg, Germany
Test targets
Methods
  • C Sequence analysis of the entire coding region

CepiSEEK® Focus Epilepsy Panel

Lab: Courtagen Diagnostics Laboratory Courtagen Life Sciences Woburn, Massachusetts, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
Total conditions (101)
Total targets (75)

CMigraine Panel

Lab: CeGaT GmbH Tuebingen, Baden-Wurttemberg, Germany
Total conditions (5)
Total targets (10)

CComprehensive Epilepsy Panel

Lab: GeneDx Gaithersburg, Maryland, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
Total conditions (55)
Total targets (70)

CFamilial Hemiplegic Migraine type 2

Test targets
Methods
  • S Mutation scanning of the entire coding region

CFamilial hemiplegic Migraine Type 2, ATP1A2

Lab: MVZ Dortmund Dr. Eberhard and Partner Dortmund, Nordrhein-Westfalen, Germany
Test targets
Methods
  • C Sequence analysis of the entire coding region

Showing 1 to 20 of 40 tests for 1538 conditions in 18 labs

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.